Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BR61
UPID:
ACBD6_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BR61
Background:
Acyl-CoA-binding domain-containing protein 6 plays a crucial role in cellular lipid metabolism by binding long-chain acyl-coenzyme A molecules. It exhibits a strong preference for unsaturated C18:1-CoA, demonstrating lower affinity for unsaturated C20:4-CoA, and very weak affinity for saturated C16:0-CoA, highlighting its selectivity in lipid binding.
Therapeutic significance:
Understanding the role of Acyl-CoA-binding domain-containing protein 6 could open doors to potential therapeutic strategies. Its involvement in lipid metabolism suggests its potential impact on metabolic disorders, offering a promising avenue for research into novel treatments.